ALQGC.PA
Quantum Genomics Société Anonyme [ALQGC.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALQGC.PA Stock Summary
Top 10 Correlated Stocks
ALQGC.PA
In the News
ALQGC.PA Financial details
Company Rating
Neutral
Market Cap
3.96M
Income
-28.11M
Revenue
1.31M
Book val./share
0.01
Cash/share
0.1
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
26 May 2024
P/E
0
Forward P/E
-
PEG
-
P/S
5.98
P/B
-
P/C
1.1
P/FCF
-0.18
Quick Ratio
0.61
Current Ratio
1.38
Debt / Equity
6.22
LT Debt / Equity
4.49
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-87.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.06%
Revenue last 5Y
-63.47%
Revenue Q/Q
-
EPS Q/Q
-40.28%
-
-
-
-
SMA20
10%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
-367%
ROC
-4.5%
Gross Margin
-4777%
Oper. Margin
-4973%
Profit Margin
-4617%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0804-0.195
52W High
-
52W Low
-
RSI
55.97
Rel Volume
1.87
Avg Volume
115.44K
Volume
215.33K
Perf Week
9.54%
Perf Month
5.96%
Perf Quarter
10.64%
Perf Half Y
-24%
-
-
-
-
Beta
0.714
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.1102
Change
0.18%
ALQGC.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.09 | 0.09 | 0.12 | 0.07 | 0 | |
| Net income per share | -0.59 | -0.79 | -0.64 | -0.72 | -0.09 | |
| Operating cash flow per share | -0.62 | -0.59 | -0.63 | -0.59 | 0 | |
| Free cash flow per share | -0.63 | -0.61 | -0.63 | -0.59 | 0 | |
| Cash per share | 0.68 | 1.34 | 0.51 | 0.3 | 0.1 | |
| Book value per share | 0.56 | 1.21 | 0.36 | 0.1 | 0.01 | |
| Tangible book value per share | 0.54 | 1.17 | 0.34 | 0.1 | 0.01 | |
| Share holders equity per share | 0.56 | 1.21 | 0.36 | 0.1 | 0.01 | |
| Interest debt per share | 0.03 | 0.11 | 0.12 | 0.07 | 0.08 | |
| Market cap | 56.72M | 100.02M | 115.56M | 4.07M | 3.66M | |
| Enterprise value | 45.56M | 73.75M | 105.47M | -3.29M | 2.82M | |
| P/E ratio | -5.74 | -6.16 | -6.66 | -0.16 | -1.15 | |
| Price to sales ratio | 36.67 | 54.68 | 36.83 | 1.62 | 363.37 | |
| POCF ratio | -5.44 | -8.34 | -6.79 | -0.2 | 0 | |
| PFCF ratio | -5.38 | -8.06 | -6.77 | -0.2 | 0 | |
| P/B Ratio | 6.03 | 4.06 | 11.95 | 1.13 | 8.37 | |
| PTB ratio | 6.03 | 4.06 | 11.95 | 1.13 | 8.37 | |
| EV to sales | 29.45 | 40.32 | 33.61 | -1.31 | 280.81 | |
| Enterprise value over EBITDA | -4.62 | -4.42 | -5.35 | 0.11 | -0.9 | |
| EV to operating cash flow | -4.37 | -6.15 | -6.2 | 0.16 | 0 | |
| EV to free cash flow | -4.32 | -5.95 | -6.18 | 0.16 | 0 | |
| Earnings yield | -0.17 | -0.16 | -0.15 | -6.12 | -0.87 | |
| Free cash flow yield | -0.19 | -0.12 | -0.15 | -4.96 | 0 | |
| Debt to equity | 0.05 | 0.03 | 0.33 | 0.67 | 6.22 | |
| Debt to assets | 0.03 | 0.03 | 0.15 | 0.1 | 0.73 | |
| Net debt to EBITDA | 1.13 | 1.57 | 0.51 | 0.25 | 0.26 | |
| Current ratio | 3.26 | 4.38 | 2.57 | 1.33 | 2.73 | |
| Interest coverage | 0 | -11.56 | -437.24 | -1.7K | -147.34 | |
| Income quality | 1.05 | 0.74 | 0.98 | 0.81 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 6.73 | 5.32 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.03 | 0 | 0 | 0 | |
| Capex to revenue | -0.07 | -0.22 | -0.01 | 0 | 0 | |
| Capex to depreciation | -0.76 | -3 | -0.12 | 0 | 0 | |
| Stock based compensation to revenue | 0.56 | 0.81 | 0.5 | 0 | 0 | |
| Graham number | 2.73 | 4.65 | 2.28 | 1.3 | 0.16 | |
| ROIC | -1 | -0.58 | -1.34 | -5.46 | -0.99 | |
| Return on tangible assets | -0.69 | -0.51 | -0.84 | -1.05 | -0.85 | |
| Graham Net | 0.35 | 1.14 | 0.25 | -0.19 | 0.01 | |
| Working capital | 9.76M | 24.56M | 12.37M | 5.81M | 2.34M | |
| Tangible asset value | 9.05M | 23.89M | 9.13M | 3.61M | 436.66K | |
| Net current asset value | 8.71M | 23.68M | 8.66M | 3.34M | 377.14K | |
| Invested capital | 0.05 | 0.03 | 0.33 | 0.67 | 6.22 | |
| Average receivables | -166.49K | 1.9M | 5.11M | 9.5M | 6.51M | |
| Average payables | 4.04M | 4.64M | 6.33M | 11.38M | 8.14M | |
| Average inventory | 377.44K | 1.04M | 873.41K | -6.45M | -6.45M | |
| Days sales outstanding | -78.56 | 824.39 | 708.48 | 1.87K | 4.32K | |
| Days payables outstanding | 161.71 | 129.15 | 121.03 | 198.05 | 32.84 | |
| Days of inventory on hand | 16.06 | 38.1 | 0 | -159.6 | 0 | |
| Receivables turnover | -4.65 | 0.44 | 0.52 | 0.19 | 0.08 | |
| Payables turnover | 2.26 | 2.83 | 3.02 | 1.84 | 11.12 | |
| Inventory turnover | 22.73 | 9.58 | 0 | -2.29 | 0 | |
| ROE | -1.05 | -0.66 | -1.8 | -6.91 | -7.26 | |
| Capex per share | -0.01 | -0.02 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.13 | 0.03 | 0.01 | 0 | 0 | |
| Net income per share | -0.41 | -0.4 | -0.32 | -0.06 | -0.03 | |
| Operating cash flow per share | -0.42 | -0.37 | -0.23 | -0.22 | 0 | |
| Free cash flow per share | -0.42 | -0.37 | -0.23 | -0.22 | 0 | |
| Cash per share | 0.51 | 0.66 | 0.26 | 0.08 | 0.1 | |
| Book value per share | 0.36 | 0.51 | 0.09 | 0.05 | 0.01 | |
| Tangible book value per share | 0.34 | 0.5 | 0.09 | 0.05 | 0.01 | |
| Share holders equity per share | 0.36 | 0.51 | 0.09 | 0.05 | 0.01 | |
| Interest debt per share | 0.11 | 0.11 | 0.06 | 0.08 | 0.08 | |
| Market cap | 116.04M | 57.51M | 4.74M | 5.77M | 3.66M | |
| Enterprise value | 105.49M | 41.46M | -2.63M | 5.92M | 2.82M | |
| P/E ratio | -2.6 | -1.2 | -0.09 | -0.73 | -0.77 | |
| Price to sales ratio | 33.78 | 64.11 | 11.79 | 573.16 | 0 | |
| POCF ratio | -10.3 | -5.18 | -0.52 | -0.75 | 0 | |
| PFCF ratio | -10.27 | -5.18 | -0.52 | -0.75 | 0 | |
| P/B Ratio | 12 | 3.75 | 1.31 | 3.55 | 8.37 | |
| PTB ratio | 12 | 3.75 | 1.31 | 3.55 | 8.37 | |
| EV to sales | 30.71 | 46.22 | -6.54 | 588.14 | 0 | |
| Enterprise value over EBITDA | -10.82 | -3.27 | 0.14 | -2.96 | -2.46 | |
| EV to operating cash flow | -9.36 | -3.74 | 0.29 | -0.77 | 0 | |
| EV to free cash flow | -9.34 | -3.74 | 0.29 | -0.77 | 0 | |
| Earnings yield | -0.1 | -0.21 | -2.74 | -0.34 | -0.32 | |
| Free cash flow yield | -0.1 | -0.19 | -1.92 | -1.32 | 0 | |
| Debt to equity | 0.3 | 0.21 | 0.67 | 1.79 | 6.22 | |
| Debt to assets | 0.14 | 0.12 | 0.1 | 0.51 | 0.73 | |
| Net debt to EBITDA | 1.08 | 1.27 | 0.4 | -0.08 | 0.72 | |
| Current ratio | 2.57 | 3.18 | 1.33 | 4.61 | 2.73 | |
| Interest coverage | 0 | -87.45 | 0 | -145.76 | -150.16 | |
| Income quality | 1.01 | 0.93 | 0.7 | 3.85 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.02 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | 0.01 | 0 | 0 | |
| Capex to depreciation | -0.11 | -0.02 | 0.04 | 0 | 0 | |
| Stock based compensation to revenue | 0.46 | 0 | -1.39 | 0 | 0 | |
| Graham number | 1.82 | 2.15 | 0.81 | 0.25 | 0.1 | |
| ROIC | -0.9 | -0.63 | -3.57 | -0.44 | -0.36 | |
| Return on tangible assets | -0.54 | -0.45 | -0.55 | -0.34 | -0.32 | |
| Graham Net | 0.1 | 0.34 | -0.24 | 0.02 | 0.01 | |
| Working capital | 12.37M | 17.98M | 5.81M | 4.42M | 2.34M | |
| Tangible asset value | 9.13M | 14.93M | 3.61M | 1.62M | 436.66K | |
| Net current asset value | 8.66M | 14.51M | 3.34M | 1.51M | 377.14K | |
| Invested capital | 0.3 | 0.21 | 0.67 | 1.79 | 6.22 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 18.23 | 299 | 0 | 25.4K | 0 | |
| Days payables outstanding | 61.22 | 44.16 | 82.26 | 25.23 | 6.37K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 4.94 | 0.3 | 0 | 0 | 0 | |
| Payables turnover | 1.47 | 2.04 | 1.09 | 3.57 | 0.01 | |
| Inventory turnover | 0 | 11.61M | 0 | 0 | 0 | |
| ROE | -1.16 | -0.78 | -3.6 | -1.22 | -2.71 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ALQGC.PA Frequently Asked Questions
What is Quantum Genomics Société Anonyme stock symbol ?
Quantum Genomics Société Anonyme is a FR stock and trading under the symbol ALQGC.PA
What is Quantum Genomics Société Anonyme stock quote today ?
Quantum Genomics Société Anonyme stock price is $0.1102 today.
Is Quantum Genomics Société Anonyme stock public?
Yes, Quantum Genomics Société Anonyme is a publicly traded company.
Company Profile
- Volume Average 115.44K
- Market Capitalization 3.96M
- Employee 3
- CEO Dr. Jean-Philippe Milon Ph.D.
- Headquarters Paris,FR
- IPO Date 2010-05-28
-
Website
https://www.quantum-genomics.com 
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
